UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanced niclosamide-based program for COVID-19 (UNI911) to clinical development, currently […]
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become ‘best-in-class’ based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical) PDE4 compound series strengthens […]
UNION receives approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19
Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has leveraged existing deep knowledge of niclosamide, derivatives and […]